Patients with PTEN-deficient prostate cancer showed improvement in progression-free survival on Truqap plus standard therapy compared to standard therapy alone.

The patient died from complications linked to a rare hyperinflammatory syndrome associated with exposure to high doses of the AAV therapy delivery vehicle.

In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) as a treatment for advanced HER2-positive biliary tract cancer.

NEW YORK – Neuron23 this week detailed the design of its global Phase II trial, dubbed NEULARK, in which it is investigating a precision treatment strategy in early Parkinson's disease. Within the ...

NEW YORK – Aptose Biosciences on Wednesday said it began testing its multi-kinase inhibitor tuspetinib with azacitidine and AbbVie and Genentech's Venclexta (venetoclax) in a Phase I/II trial as a ...